Clinical trials

  • Pseudovax hydrochloride for Pseudomyxoma peritonei
  • Refined and quantified dry extract of Ginkgo biloba leaves (35-67:1) quantified to 22.0 to 27.0 % of flavonoids (expressed as flavone glycosides), 2.8 to 3.4 % of ginkgolides A, B and C, and 2.6 to 3.2 % of bilobalide. Extraction solvent: acetone 60% (m/m) for Cognitive impairment associated with post-COVID-19 syndrome|Post-acute COVID-19 syndrome
  • N-SULFOGLUCOSAMINE SULFOHYDROLASE FUSED TO A HUMANISED MONOCLONAL ANTIBODY TARGETING HUMAN TRANSFERRIN RECEPTOR for Mucopolysaccharidosis type IIIA (MPS IIIA)
  • Clinical trial in Cholangitis
  • DAPAGLIFLOZIN PROPANEDIOL for Chronic kidney disease
  • N/A for Cervical dysplasia|Human papillomavirus (HPV) infection|Cervical intraepithelial neoplasia (CIN2+)
  • Budesonide for Functional dyspepsia
  • ABBV-CLS-628 for Autosomal dominant polycystic kidney disease (ADPKD)
  • CASCS for Heart failure | Ischemic heart failure | Chronic myocardial infarction
  • KT-621 for Moderate to severe atopic dermatitis|Atopic dermatitis
  • BOSENTAN for Giant cell arteritis
  • FUTIBATINIB for Colorectal cancer